Medtech Execs On The Move, April 2014
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
You may also be interested in...
US FDA commissioner Stephen Hahn and ORA associate commissioner for regulatory affairs Judith McMeekin said in a joint 24 February statement that the agency continues to aggressively monitor the market for any firms selling products with fraudulent COVID-19 prevention and treatment claims. The officials also explained that the FDA has the authority to ask for records from drug manufacturers in lieu of conducting facility inspections, but they didn’t say whether the agency would – or even could – ask the same of device makers. The FDA had announced on 14 February that it paused all inspections of Chinese manufacturing facilities in the near-term.
Knee implant manufacturer Conformis Inc. brings aboard new chief financial officer/treasurer and operations SVP; imaging and data management software company EyeKor promoted its president/CTO to CEO; and more.
Oncologic Drugs Advisory Committee will consider whether a statistically significant benefit on progression-free survival, but no survival advantage, is enough to secure a first-line lung cancer indication for ramucirumab.